LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Improved clinical trial race/ethnicity reporting and updated inclusion profile, 2017-2022: A New Jersey snapshot.

    Paleoudis, Elli Gourna / Han, Zhiyong / Gelman, Simon / Arias-Ruiz, Hernan / Carter, Destiney / Bertrand, Jovan / Mastrogiovanni, Nicole / Terlecky, Stanley R

    Global epidemiology

    2023  Volume 7, Page(s) 100134

    Abstract: Background: Diverse representation in clinical trials is an important goal in the testing of a medical, diagnostic, or therapeutic intervention. To date, the desired level of trial equity and inclusivity has been unevenly achieved.: Methods: ... ...

    Abstract Background: Diverse representation in clinical trials is an important goal in the testing of a medical, diagnostic, or therapeutic intervention. To date, the desired level of trial equity and inclusivity has been unevenly achieved.
    Methods: Employing the US National Library of Medicine's Clinicaltrials.gov registry, we examined 481 clinical trials conducted - at least in part - in the state of New Jersey. These trials were initiated after the FDA-mandated Common Rule changes, i.e., between January 2017 and October 2022, were enacted, and had their results posted. We analyzed sex/race/ethnicity reporting as well as applicable enrollment. Using meta-analysis, we estimated group participation proportions of a subset of the 481 identified trials; specifically, the 229 studies that were conducted solely within the US (i.e., without international sites) and compared them to US census data.
    Findings: Within the 481 clinical trials analyzed, over 97% reported on the race and/or ethnicity of their enrollees; all included information on sex. Reporting was not affected by funding source or therapeutic area. Based on the 229 solely US-based studies, the participants overall were 76.7% White; 14.1% Black; 2.7% Asian; and 15% Hispanic. Inclusion of Black participants did not differ from the 2020 US census data; in contrast, the levels of Asian and Hispanic participation were below the corresponding census percentages.
    Interpretation: The past five years have seen an overall uptick in the equity of race/ethnicity reporting and inclusivity of clinical trials, as compared to previously reported data, presaging the potential acquisition of ever more powerful and meaningful results of such interventional studies going forward.
    Funding: Support for this study comes from the Hackensack Meridian
    Research in context: Evidence before this study
    Language English
    Publishing date 2023-12-23
    Publishing country United States
    Document type Journal Article
    ISSN 2590-1133
    ISSN (online) 2590-1133
    DOI 10.1016/j.gloepi.2023.100134
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: Relationship between the Soluble F11 Receptor and Annexin A5 in African Americans Patients with Type-2 Diabetes Mellitus.

    Adedayo, Ajibola / Eluwole, Ayobami / Tedla, Fasika / Kremer, Arye / Khan, Muhammad / Mastrogiovanni, Nicole / Rosenberg, Carl / Dreizen, Paul / La Rosa, John / Salciccioli, Louis / Boutjdir, Mohamed / Banerji, Mary Ann / Brown, Clinton / Lazar, Jason / Salifu, Moro / Bakillah, Ahmed

    Biomedicines

    2022  Volume 10, Issue 8

    Abstract: Type 2 diabetes mellitus (T2DM) is characterized by endothelial dysfunction, increased thrombogenicity, and inflammation. The soluble human F11 receptor (sF11R) and annexin A5 (ANXA5) play crucial roles in inflammatory thrombosis and atherosclerosis. We ... ...

    Abstract Type 2 diabetes mellitus (T2DM) is characterized by endothelial dysfunction, increased thrombogenicity, and inflammation. The soluble human F11 receptor (sF11R) and annexin A5 (ANXA5) play crucial roles in inflammatory thrombosis and atherosclerosis. We examined the relationship between circulating sF11R and ANXA5 and their impact on endothelial function. The study included 125 patients with T2DM. Plasma levels of sF11R and ANXA5 were quantified by ELISA. Microvascular function was assessed using the vascular reactivity index (VRI). Large artery stiffness was assessed by carotid-femoral pulse wave velocity (PWV). Carotid intima-media thickness (CIMT) was assessed by B-mode ultrasound imaging. The mean age of patients in the study was 59.7 ± 7.8 years, 78% had hypertension, 76% had dyslipidemia, and 12% had CKD. sF11R correlated positively with ANXA5 levels (β = 0.250, p = 0.005), and correlated inversely with VRI and total nitic oxide (NO), (β = −0.201, p = 0.024; β = −0.357, p = 0.0001, respectively). Multivariate regression analysis revealed that sF11R was independently associated with ANXA5 in the total population and in patients with HbA1c > 6.5% (β = 0.366, p = 0.007; β = 0.425, p = 0.0001, respectively). sF11R and ANXA5 were not associated with vascular outcome, suggesting that they may not be reliable markers of vascular dysfunction in diabetes. The clinical significance of sF11R/ANXA5 association in diabetes warrants further investigation in a larger population.
    Language English
    Publishing date 2022-07-28
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2720867-9
    ISSN 2227-9059
    ISSN 2227-9059
    DOI 10.3390/biomedicines10081818
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Association between nitrated lipoproteins and vascular function in type 2 diabetes.

    Adedayo, Ajibola / Eluwole, Ayobami / Tedla, Fasika / Kremer, Arye / Mastrogiovanni, Nicole / Khan, Muhammad / Rosenberg, Carl / Dreizen, Paul / La Rosa, John / Salciccioli, Louis / Boutjdir, Mohamed / Banerji, Mary Ann / Brown, Clinton / Salifu, Moro / Lazar, Jason / Bakillah, Ahmed

    Frontiers in bioscience (Landmark edition)

    2021  Volume 26, Issue 4, Page(s) 644–663

    Abstract: Higher levels of nitrated lipoproteins (NT-HDL and NT-LDL) were found in blood and atherosclerotic plaques of patients with coronary artery disease. We aimed to examine the relationship between plasma NT-HDL and NT-LDL and diabetic vascular dysfunction. ... ...

    Abstract Higher levels of nitrated lipoproteins (NT-HDL and NT-LDL) were found in blood and atherosclerotic plaques of patients with coronary artery disease. We aimed to examine the relationship between plasma NT-HDL and NT-LDL and diabetic vascular dysfunction. The study included 125 African-American patients with T2DM. NT-HDL and NT-LDL were quantified by ELISA. Microvascular function was assessed by vascular reactivity index (VRI). Large artery stiffness was assessed by carotid-femoral pulse wave velocity (PWV). Carotid intima-media thickness (CIMT) was assessed by B-mode ultrasound imaging. In univariate analysis, NT-HDL was associated with VRI in total population and in patients with HbA1c more than or equal to 7.0 percent (beta= -0.178, p= 0.034; beta = -0.265, p= 0.042; respectively). In contrast, NT-LDL was associated with CIMT in total population and in patients with HbA1c more than 7.0 percent (beta = -0.205, p= 0.022; beta = -0.244, p= 0.042; respectively). Multivariable-adjusted regression analysis demonstrated that NT-HDL independently predicted VRI outcome in total population and in well-controlled patients (beta = -0.282, p= 0.014; beta = -0.400, p= 0.035, respectively). These results suggest that NT-HDL could be used as marker to identify diabetic patients at risk of developing early microvascular complications.
    MeSH term(s) Aged ; Biomarkers/blood ; Blood Vessels/physiopathology ; Case-Control Studies ; Cholesterol, HDL/blood ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/physiopathology ; Diabetic Angiopathies/blood ; Diabetic Angiopathies/complications ; Diabetic Angiopathies/physiopathology ; Enzyme-Linked Immunosorbent Assay ; Female ; Glycated Hemoglobin A/metabolism ; Humans ; Lipoproteins/blood ; Male ; Middle Aged ; Multivariate Analysis ; Nitrates/blood ; Risk Factors
    Chemical Substances Biomarkers ; Cholesterol, HDL ; Glycated Hemoglobin A ; Lipoproteins ; Nitrates ; hemoglobin A1c protein, human
    Language English
    Publishing date 2021-01-01
    Publishing country Singapore
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2704569-9
    ISSN 2768-6698 ; 1093-9946
    ISSN (online) 2768-6698
    ISSN 1093-9946
    DOI 10.2741/4910
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top